All News

podcast logo

RheumNow Podcast – COVID-19 Responds to Steroids (7.24.20)

d Jack Cush, MD

Dr. Jack Cush reviews the News and Journal Reports from the past week on RheumNow.com.

Read Article
Single center retrospective Korean study of 1280 Ankylosing Spondylitis patients (595 exposed to TNFi) showed that TNFi was associated with significantly decreased Xray change rate (mSASSS) (β=−0.112, p=0.004). https://t.co/W4j0Ckt0R2

Links:

Dr. John Cush RheumNow ( View Tweet)

podcast logo

RheumNow Podcast – Lupus Mortality Declines, But… (6.26.20)

d Jack Cush, MD

Dr Jack Cush reviews the news and journal articles from the past week on RheumNow.com

Read Article
backpain.hip_.jpg (keep)

Cosentyx FDA Approval for Non-Radiographic Axial Spondyloarthritis

d Jack Cush, MD

Yesterday the FDA approved secukinumab (Cosentyx) for the treatment of patients with active non-radiographic axial spondyloarthritis (nr-axSpA). There are now three agents that are FDA approved for nr-axSpA: certolizumab, ixekizumab and now, secukinumab. 

Read Article
List.jpg (keep)

Day 4 - Top 3 from EULAR 2020

d Jack Cush, MD

These were my top abstracts from Thursday, 4th of June at EULAR 2020:

Read Article
#EULAR2020 #op0079 ASAS-MRI group offers updated definition of the structural lesions in SI joints in AxSpA: -erosion in >=2 consecutive slices or in >=3 SIJ quadrants - fat lesions w/depth >1cm in >=1SIJ quadrant are high priority candidates @RheumNow https://t.co/EU1WWqJ4h3
Olga Petryna DrPetryna ( View Tweet)
How often do you use MRI of peripheral joints for diagnosis or monitoring of PsA?

Olga Petryna DrPetryna ( View Tweet)

#EULAR2020 #op0182 delayed gadolinium-enhanced MRI study reveals proteoglycan loss in articulate cartilage in PsA associated w/severity of periarticular inflammation, synovitis &flexor tenosynovits but not bone erosion or prolypheration. @RheumNow https://t.co/ZJBDnZuYbB
Olga Petryna DrPetryna ( View Tweet)
#eular2020 #op0314 5 y drug-free remission (5DFR) is rare in early AxSpA: 17%pts from DESIR cohort reach 5DFR. Shorter disease duration (<1.3y), lower BASDAI&ASAS-CRP & less peripheral involv more likely to achieve DFR. Imaging and biological data did not predict DFR @RheumNow

Olga Petryna DrPetryna ( View Tweet)

#EULAR2020 #op0327 AI stages knee OA radiograpgic chsnges ieth accuracy 91.8-99% in 95% of the cases. Would you prefer AI or human radiology readings for MSK imaging ? @RheumNow

Olga Petryna DrPetryna ( View Tweet)

Sustained clinical response shown over the 10 yrs of this German study in r-axSpA and nr-axSpA pts treated with ETN. No new safety signals. Abstract #AB0660 #EULAR2020 @RheumNow https://t.co/KCMDyzHaSr https://t.co/yFSTgWqzBQ

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
The Relative Diagnostic Utility of inflamm back pain criteria in inception cohort with PsO, Iritis, & Colitis Presenting With Undiagnosed Back Pain: All IBP criteria have poor diagnostic utility for dx of axSpA, esp in PsO Abs SAT0378 #EULAR2020 @RheumNow https://t.co/Y7sbtJtm3U https://t.co/P9q7uJozZ9

Links:

Dr Philip Robinson philipcrobinson ( View Tweet)
Filgotinib was associated with significant reduction in SIJ erosion scores in axSpA: imaging data from the double-blind, randomized Tortuga trial #EULAR2020 @rheumnow THU0377 https://t.co/1b18Uyvo5j https://t.co/zBXCwGc0Q7

Links:

Dr Philip Robinson philipcrobinson ( View Tweet)
Replacing radiographic sacroiliitis with MRI structural damage doesn't change the classifciation of axSpA signifciantly @RheumNow #EULAR2020 Abstract SAT0384 https://t.co/MTTf4fHjYT
Dr Philip Robinson philipcrobinson ( View Tweet)
Preliminary definition of a +MRI for struc lesions in the SIJs in axSpA: Erosion in ≥2 consec slices or in ≥3 SIJ quad and fat lesion w depth >1cm in ≥1 SIJ quad are high priority for def an MRI struc lesion of axSpA. Abs OP0079 #EULAR2020 @RheumNow https://t.co/9RlSOUviJQ https://t.co/l4XiQDj8e4

Links:

Dr Philip Robinson philipcrobinson ( View Tweet)
Spanish COSPAR registry results reveal changes in axSpA pt gut microbiota which are associated with radiographic damage, disease activity, affectation of enthesis and axial mobility. #SAT0362 https://t.co/goo4Qkaqdb #EULAR2020 @RheumNow

Links:

Dr. Rachel Tate uptoTate ( View Tweet)

Another study shows that US guided SIJs in axSpA pts are safe and effective. Abstract #AB0642. #EULAR2020 @RheumNow https://t.co/KMPioCKr0n

Links:

Dr. Rachel Tate uptoTate ( View Tweet)

backpain.hip_.jpg (keep)

FDA Approves Taltz for Non-Radiographic Axial Spondyloarthritis

d Jack Cush, MD

Today Eli Lilly announced that Taltz (ixekizumab) has received FDA approval for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA).

Read Article
janefingr.JPG

Systemic Sclerosis Future Therapies and Outcome Measures

d Jack Cush, MD

Nagaraja, Khanna and colleagues have published an overview of current and future therapies in patients with systemic sclerosis (SSc) and have reviewed the potential outcome measures for this difficult autoimmune disorder.

Read Article
smoking.jpg

Cigarette Smoking and ANCA-Associated Vasculitis

d Jack Cush, MD

JAMA Internal Medicine has reported that cigarette smoking associated with an increased odds of having antineutrophil cytoplasmic antibody–associated vasculitis (AAV) (especially MPO positive AAV) and is thereby a modifiable risk factor for AAV.

Read Article

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.